We are currently part of a multi-center double-blinded controlled drug trial that is studying the effects a new drug has on treating diffuse pain associated with Mast Cell Activation Syndrome.
What is Mast Cell Activation Syndrome?
Mast Cell Activation Syndrome, or MCAS, is a condition in which a patient suffers from various allergic reactions, and the cells that are released in the body during these episodes are called mast cells. The mediators within the mast cells are released in higher than normal amounts, and happen without any clear reasoning.
Patients with MCAS often have diffuse pain as well as other systemic conditions (hives, dermatographia (skin turns pink when lightly scratched), diarrhea, fast heart rate, shortness of breath, nausea, etc.). By blocking mast cells, diffuse pain can be relieved.
Each person participating in this study will be asked to be a part of a drug trial, in which you will be taking medication for two months, with consistent follow-up (in person and over the phone, along with filling in questionnaires online). This is a randomized, placebo-controlled study, meaning that you will either be given study drug or placebo. A placebo looks like the study drug but does not have any active or medical ingredients.
Participants will be compensated up to $50 for transportation and meals every time they come to our office.
The study takes approximately 3 months to complete and participants must be able to come to our office for frequent visits (5 visits in total), be between the ages of 18 and 75, and be in general good health. Female participants may not be pregnant or breastfeeding at the time of study.